Fexofenadine is the generic name for the allergy medication sold under the brand name Allegra and in many store brand versions. It is a second generation, non sedating antihistamine that millions of people take for seasonal allergies, hives, and other histamine related symptoms. Employers and employees sometimes ask whether an over the counter or prescription antihistamine like fexofenadine can trigger a positive result on a workplace urine drug screen. This article explains what fexofenadine is, whether it is a controlled substance, what the published evidence says about cross reactivity with standard drug test panels, and what happens when a donor reports taking an antihistamine before a screening.
What fexofenadine is and how it is classified
Fexofenadine hydrochloride is a second generation H1 antihistamine, chemically distinct from first generation antihistamines such as diphenhydramine. The current prescribing information and product listings are maintained on DailyMed, the National Library of Medicine's database of official drug labeling, and consumer level information on dosing forms and uses is summarized by the National Library of Medicine at MedlinePlus Drug Information. Fexofenadine is not listed on any Drug Enforcement Administration controlled substance schedule, and it is sold both over the counter and by prescription depending on strength and formulation. Its original new drug application history is on file with the FDA at Drugs@FDA. Because it is not a scheduled controlled substance, it is not an analyte that any standard drug test panel is built to detect.
Why second generation antihistamines differ from diphenhydramine
The distinction between first and second generation antihistamines matters for interference questions. First generation antihistamines, most notably diphenhydramine, are more lipophilic, cross the blood brain barrier more readily, and have a documented history of case reports describing cross reactivity with certain immunoassay screens, particularly for PCP class results, because of structural similarity at the antibody binding site used in some assay kits. Second generation antihistamines like fexofenadine, loratadine, and cetirizine were specifically developed to reduce sedation and central nervous system penetration, and they have a different molecular structure and metabolic pathway than diphenhydramine. That structural difference is the reason interference reports cluster around first generation antihistamines rather than second generation ones. A difference in chemical class does not promise zero interference with every assay from every manufacturer, but it is the basis for why fexofenadine is not grouped with diphenhydramine in interference discussions.
What the published record says about fexofenadine specifically
There is no published, peer reviewed cross reactivity data showing that fexofenadine produces a false positive result on standard 5 panel, 10 panel, or 12 panel immunoassay drug screens for amphetamines, opioids, cocaine metabolite, THC, PCP, or other commonly screened analyte classes. Manufacturers of immunoassay test kits publish cross reactant lists as part of their package inserts, and the FDA maintains premarket clearance records for cleared point of care test systems, searchable through the agency's device databases at FDA 510(k) Premarket Notification database. Where a specific cross reactant is not identified in a cleared assay's labeling and no published case series or toxicology literature documents interference for a given compound, the accurate statement is that there is no published cross reactivity evidence for that compound, not that interference is impossible under every circumstance with every test. For fexofenadine, the honest answer based on the current record is no published cross reactivity with standard immunoassay drug screens.
Allergy medications and interference notes
| Medication | Antihistamine generation | Interference pattern reported |
|---|---|---|
| Fexofenadine (Allegra) | Second generation | No published cross reactivity with standard immunoassay panels |
| Loratadine (Claritin) | Second generation | No published cross reactivity with standard immunoassay panels |
| Cetirizine (Zyrtec) | Second generation | No published cross reactivity with standard immunoassay panels |
| Diphenhydramine (Benadryl) | First generation | Case reports of interference with PCP class immunoassay screens; see our related post below |
| Doxylamine | First generation | Structurally related to diphenhydramine; similar interference concerns described in case literature |
This table reflects published interference patterns at the class level. It is not a promise that any individual test kit lot, instrument, or laboratory will behave identically, and it is not medical advice about which allergy medication to take.
How GC/MS or LC/MS confirmation resolves a presumptive result
Immunoassay screening, whether run on a point of care cup, dip card, or an instrument at a laboratory, is a presumptive test. It is designed to be fast and inexpensive, and it works by detecting whether a sample binds to antibodies tuned to a target drug class, which is also the mechanism that allows unrelated compounds to occasionally cause a nonspecific reaction. A presumptive positive on a screening immunoassay is never the final word. Samples that screen positive are routinely sent for confirmation testing using gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS), which identify the specific molecule present rather than a class level antibody reaction. Confirmation testing is the step that distinguishes an actual controlled substance from an unrelated compound that happened to cross react on the screen. Because fexofenadine is not a controlled substance and has no documented cross reactivity profile, a donor taking only fexofenadine would not be expected to produce a confirmed positive for any scheduled drug through this process.
The MRO review and prescription documentation step
In federally regulated safety sensitive testing, such as DOT covered positions, every laboratory confirmed positive result is reviewed by a Medical Review Officer (MRO) before it is reported to the employer. The MRO contacts the donor, discusses any prescription or over the counter medications taken, and reviews documentation such as a pharmacy record or prescription label. This process is set out in federal regulation at 49 CFR Part 40, Procedures for Transportation Workplace Drug and Alcohol Testing Programs, which governs how MROs verify, interview, and document legitimate medical explanations for a laboratory result before a final determination is made. Employers running non regulated workplace testing programs commonly use a similar review model even though it is not federally mandated outside DOT covered roles, and program design guidance for drug free workplace programs generally is available from the Substance Abuse and Mental Health Services Administration at SAMHSA's drug free workplace resources. A donor who reports taking fexofenadine or any other over the counter medication should keep the packaging or a pharmacy receipt available in case questions arise during this review.
What employers should do with a disputed result
If a donor disputes a screening result and states they only took an over the counter antihistamine, the correct response is to follow the program's standard procedure rather than make an independent medical judgment. That means routing the sample to confirmation testing if it has not already been confirmed, allowing the MRO or a qualified reviewing authority to interview the donor and evaluate documentation, and keeping the review process consistent for every donor regardless of what medication is named. Employers should not attempt to diagnose, question the donor about dosing or timing of a medication, or make a final employment decision before the MRO or equivalent review step is complete. Because no credible published evidence links fexofenadine to a false positive, a confirmed positive result in a donor who reports taking only fexofenadine would not be explained by the antihistamine, and the review should look at the actual confirmed analyte rather than assume the allergy medication is the cause.
Frequently asked questions
Is fexofenadine a controlled substance?
No. Fexofenadine is not listed on any DEA controlled substance schedule. It is available over the counter and by prescription depending on the formulation and strength, as reflected in its FDA labeling on DailyMed.
Can fexofenadine make a drug test come back positive for amphetamines or PCP?
There is no published cross reactivity evidence showing fexofenadine causes a false positive on standard immunoassay panels for amphetamines, PCP, or other commonly screened drug classes. This differs from first generation antihistamines like diphenhydramine, which have documented case reports of interference with certain PCP class screens.
Does a positive screening result mean a donor definitely has an illegal drug in their system?
No. A positive immunoassay screen is presumptive. Confirmation testing by GC/MS or LC/MS identifies the specific substance and is required before a result is treated as final in regulated testing programs.
What should someone do if they are taking fexofenadine before a scheduled drug test?
They should disclose current medications if asked during the testing or review process and keep packaging or a pharmacy record available. This is informational guidance, not medical advice, and any medication decisions should be discussed with a healthcare provider.
Who reviews a positive result for a legitimate medical explanation?
In DOT regulated testing, a Medical Review Officer reviews every laboratory confirmed positive result under the process set out in 49 CFR Part 40. Many non regulated employers use a similar review model as part of their drug free workplace program.
Where can employers find reliable drug test cups and dip cards for a workplace program?
American Screening Corporation supplies drug test cups, dip cards, and oral fluid tests for workplace programs. See the drug test cup collection for current options.
Related reading
- Benadryl and Drug Tests: Diphenhydramine False Positives Explained
- Does Hydroxyzine Show Up on a Drug Test? Antihistamines and Standard Panels
This article is general information for employers and employees about drug testing science and procedure. It is not legal advice or medical advice. Employers should consult qualified counsel and a Medical Review Officer for decisions involving specific test results.
